Evogene (EVGN) Competitors $1.37 -0.08 (-5.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.44 +0.06 (+4.74%) As of 07/11/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, TOMZ, ENFY, SDST, SNES, GURE, CNEY, NITO, BSLK, and HGASShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), TOMI Environmental Solutions (TOMZ), Enlightify (ENFY), Stardust Power (SDST), Senestech (SNES), Gulf Resources (GURE), CN Energy Group. (CNEY), N2OFF (NITO), Bolt Projects (BSLK), and Global Gas (HGAS). Evogene vs. Its Competitors Carisma Therapeutics TOMI Environmental Solutions Enlightify Stardust Power Senestech Gulf Resources CN Energy Group. N2OFF Bolt Projects Global Gas Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Do institutionals & insiders have more ownership in EVGN or CARM? 10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 12.6% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer EVGN or CARM? In the previous week, Evogene and Evogene both had 3 articles in the media. Carisma Therapeutics' average media sentiment score of 0.93 beat Evogene's score of 0.73 indicating that Carisma Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Carisma Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, EVGN or CARM? Evogene has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Do analysts recommend EVGN or CARM? Evogene currently has a consensus target price of $3.50, suggesting a potential upside of 155.47%. Carisma Therapeutics has a consensus target price of $1.93, suggesting a potential upside of 381.25%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43 Is EVGN or CARM more profitable? Evogene has a net margin of -224.82% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Evogene-224.82% -102.40% -39.19% Carisma Therapeutics -254.28%N/A -137.38% Which has preferable earnings and valuation, EVGN or CARM? Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvogene$8.51M0.86-$16.49M-$2.69-0.51Carisma Therapeutics$19.63M0.85-$60.48M-$1.56-0.26 SummaryCarisma Therapeutics beats Evogene on 10 of the 16 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.78M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E Ratio-0.5120.5827.9620.25Price / Sales0.86292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.497.638.045.49Net Income-$16.49M-$55.05M$3.18B$250.27M7 Day Performance0.74%8.54%3.68%4.80%1 Month Performance-9.87%5.51%4.10%7.68%1 Year Performance-78.43%2.03%29.59%16.36% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.681 of 5 stars$1.37-5.5%$3.50+155.5%-78.4%$7.78M$8.51M-0.51140CARMCarisma Therapeutics3.2732 of 5 stars$0.40-2.0%$1.93+387.3%-66.7%$16.84M$19.63M-0.2520TOMZTOMI Environmental Solutions3.3501 of 5 stars$1.05-2.8%$3.50+233.3%+30.7%$21.62M$7.74M-6.1820ENFYEnlightifyN/A$1.10+1.3%N/AN/A$17.57M$95.85M-0.56424Earnings ReportGap UpHigh Trading VolumeSDSTStardust Power2.9959 of 5 stars$0.21+0.6%$5.11+2,357.9%N/A$12.44MN/A-0.28N/APositive NewsHigh Trading VolumeSNESSenestech1.4239 of 5 stars$5.13-0.2%$10.00+94.9%-19.5%$11.55M$1.86M-0.6730GUREGulf Resources1.2654 of 5 stars$0.67-2.4%N/A-42.5%$9.21M$7.66M-0.12420Positive NewsCNEYCN Energy Group.0.5833 of 5 stars$2.65-1.9%N/A-78.6%$8.13M$50.96M0.00160NITON2OFF1.6764 of 5 stars$0.25+0.9%N/A-48.0%$6.53M$210K0.002News CoverageBSLKBolt ProjectsN/A$2.50-2.7%N/AN/A$5.30M$1.37M0.0012Gap DownHGASGlobal GasN/A$0.10-28.2%N/AN/A$1.15MN/A0.002Gap Down Related Companies and Tools Related Companies CARM Competitors TOMZ Competitors ENFY Competitors SDST Competitors SNES Competitors GURE Competitors CNEY Competitors NITO Competitors BSLK Competitors HGAS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
